Skip to main content

Deciphera Pharmaceuticals, Inc.

DCPHDelisted Jun 11, 2024
Industry
Pharmaceutical Preparations
SEC CIK
0001654151

Deciphera Pharmaceuticals, Inc. was delisted on Jun 11, 2024; its insiders filed their last Form 4 on Jun 11, 2024; 177 institutions reported holding it in 13F filings for Q1 2024, worth $943.7M in total; no superinvestor held it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Deciphera Pharmaceuticals, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Deciphera Pharmaceuticals, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Deciphera Pharmaceuticals, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Sherman Matthew LEVP & Chief Medical Officer0Jun 11, 20240
Allen Patricia LDirector–Jun 11, 20240
Kelly Thomas PatrickChief Financial Officer0Jun 11, 20240
Squarer RonDirector–Jun 11, 20240
Kelley Susan L.Director–Jun 11, 20240
Hoerter Steven L.President and CEO0Jun 11, 20240
Benz Edward J. JRDirector–Jun 11, 20240
Walsh Dennis LeoDirector0Jun 11, 20240
Martin John RichardDirector–Jun 11, 20240
Bristol James ArthurDirector–Jun 11, 20240
Martin Daniel C.Chief Commercial Officer0Jun 11, 20240
Dhanak DashyantEVP & Chief Scientific Officer0Jun 11, 20240
Friedman Franklin StuartDirector0Jun 11, 20240
Pitman JamaSVP, Chief Development Officer0Jun 11, 20240
Brightstar Associates LLC10% Owner23,107,844Apr 24, 20240
Flynn Daniel LeeChief Scientific Officer57,158Jun 21, 20230

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Oct 6, 2021 (view filing)Oct 42 daysSherman Matthew LEVP & Chief Medical OfficerSSale−2.66K$33.17−$88.2K−5.5%46.0K after
Feb 18, 2022 (view filing)Feb 162 daysPitman JamaSee RemarksSSale−1.15K$9.05−$10.4K−2.9%38.0K after
Feb 18, 2022 (view filing)Feb 162 daysKelly Thomas PatrickChief Financial OfficerSSale−1.37K$9.05−$12.4K−2.8%47.8K after
Feb 18, 2022 (view filing)Feb 162 daysMartin Daniel C.Chief Commercial OfficerSSale−1.15K$9.05−$10.4K−2.3%48.7K after
Feb 18, 2022 (view filing)Feb 162 daysFlynn Daniel LeeChief Scientific OfficerSSale−1.37K$9.05−$12.4K−2.8%47.9K after
Feb 18, 2022 (view filing)Feb 162 daysSherman Matthew LEVP & Chief Medical OfficerSSale−984$9.05−$8.91K−1.3%76.8K after
Apr 29, 2022 (view filing)Apr 29Same dayBrightstar Associates LLC10% OwnerPPurchase+1.48M$10.00+$14.8M+8.9%18.1M after
Apr 29, 2022 (view filing)Apr 29Same dayBrightstar Associates LLC10% OwnerPPurchase+3.39M$9.99+$33.9M–3.39M afterDerivative
Jun 21, 2022 (view filing)Jun 165 daysFlynn Daniel LeeChief Scientific OfficerSSale−1.77K$10.75−$19.0K−3.7%46.1K after
Jun 21, 2022 (view filing)Jun 165 daysKelly Thomas PatrickChief Financial OfficerSSale−1.77K$10.75−$19.0K−3.7%46.1K after
Jun 21, 2022 (view filing)Jun 165 daysMartin Daniel C.Chief Commercial OfficerSSale−1.31K$10.75−$14.1K−2.6%49.5K after
Jun 21, 2022 (view filing)Jun 165 daysPitman JamaSee RemarksSSale−1.30K$10.75−$14.0K−3.4%36.7K after
Jun 21, 2022 (view filing)Jun 165 daysSherman Matthew LEVP & Chief Medical OfficerSSale−1.77K$10.75−$19.0K−2.2%76.9K after
Oct 5, 2022 (view filing)Oct 32 daysSherman Matthew LEVP & Chief Medical OfficerSSale−2.59K$18.73−$48.5K−3.4%74.3K after
Jan 19, 2023 (view filing)Jan 172 daysKelly Thomas PatrickChief Financial OfficerSSale−2.40K$21.24−$51.0K−5.2%43.7K after
Jan 19, 2023 (view filing)Jan 172 daysMartin Daniel C.Chief Commercial OfficerSSale−1.60K$21.24−$34.0K−3.2%48.4K after
Jan 19, 2023 (view filing)Jan 172 daysSherman Matthew LEVP & Chief Medical OfficerSSale−2.40K$21.24−$51.0K−3.2%72.6K after
Jan 19, 2023 (view filing)Jan 172 daysPitman JamaSee RemarksSSale−1.60K$21.24−$34.0K−4.4%35.1K after
Jan 19, 2023 (view filing)Jan 172 daysFlynn Daniel LeeChief Scientific OfficerSSale−2.40K$21.24−$51.0K−5.2%43.7K after
Jan 24, 2023 (view filing)Jan 24Same dayBrightstar Associates LLC10% OwnerPPurchase+1.67M$18.00+$30.0M+9.2%19.7M after
Feb 16, 2023 (view filing)Feb 142 daysHoerter Steven L.President and CEOSSale−30.0K$16.00−$480.7K−80.0%7.50K after
Feb 17, 2023 (view filing)Feb 161 dayFlynn Daniel LeeChief Scientific OfficerSSale−1.37K$15.10−$20.7K−2.3%58.8K after
Feb 17, 2023 (view filing)Feb 161 daySherman Matthew LEVP & Chief Medical OfficerSSale−971$15.10−$14.7K−1.1%88.1K after
Feb 17, 2023 (view filing)Feb 161 dayKelly Thomas PatrickChief Financial OfficerSSale−1.37K$15.10−$20.7K−2.3%58.8K after
Feb 17, 2023 (view filing)Feb 161 dayMartin Daniel C.Chief Commercial OfficerSSale−1.16K$15.10−$17.5K−1.9%58.4K after
Feb 17, 2023 (view filing)Feb 161 dayPitman JamaSee RemarksSSale−1.16K$15.10−$17.5K−2.5%45.0K after
Mar 23, 2023 (view filing)Mar 212 daysHoerter Steven L.President and CEOSSale−7.50K$15.57−$116.8K−100.0%0 after
May 12, 2023 (view filing)May 102 daysWalsh Dennis LeoDirectorPPurchase+11.0K$13.86+$152.5KNew position11.0K after
Jun 12, 2023 (view filing)Jun 84 daysFriedman Franklin StuartDirectorPPurchase+10.0K$13.88+$138.8KNew position10.0K after
Jun 21, 2023 (view filing)Jun 165 daysFlynn Daniel LeeChief Scientific OfficerSSale−1.66K$14.40−$23.8K−2.8%57.2K after
Jun 21, 2023 (view filing)Jun 165 daysMartin Daniel C.Chief Commercial OfficerSSale−1.24K$14.40−$17.8K−2.1%58.4K after
Jun 21, 2023 (view filing)Jun 165 daysKelly Thomas PatrickChief Financial OfficerSSale−1.66K$14.40−$23.8K−2.8%57.1K after
Jun 21, 2023 (view filing)Jun 165 daysSherman Matthew LEVP & Chief Medical OfficerSSale−1.66K$14.40−$23.8K−1.9%87.7K after
Jun 21, 2023 (view filing)Jun 165 daysPitman JamaSee RemarksSSale−1.24K$14.40−$17.8K−2.7%43.8K after
Oct 4, 2023 (view filing)Oct 22 daysSherman Matthew LEVP & Chief Medical OfficerSSale−2.94K$12.68−$37.3K−3.4%84.7K after
Oct 31, 2023 (view filing)Oct 301 dayHoerter Steven L.President and CEOSSale−21.6K$12.02−$259.3K−34.5%40.9K after
Oct 31, 2023 (view filing)Oct 301 dayKelly Thomas PatrickChief Financial OfficerSSale−2.32K$12.02−$27.8K−3.5%63.1K after
Oct 31, 2023 (view filing)Oct 301 dayMartin Daniel C.Chief Commercial OfficerSSale−1.41K$12.02−$16.9K−2.2%62.9K after
Oct 31, 2023 (view filing)Oct 301 dayPitman JamaSee RemarksSSale−1.41K$12.02−$16.9K−2.8%48.3K after
Oct 31, 2023 (view filing)Oct 301 daySherman Matthew LEVP & Chief Medical OfficerSSale−2.36K$12.02−$28.4K−2.5%90.6K after
Dec 1, 2023 (view filing)Nov 301 dayMartin Daniel C.Chief Commercial OfficerSSale−17.8K$12.57−$223.8K−28.2%45.4K after
Dec 14, 2023 (view filing)Dec 131 daySherman Matthew LEVP & Chief Medical OfficerSSale−2.79K$15.37−$42.9K−2.8%96.5K after
Dec 14, 2023 (view filing)Dec 131 dayMartin Daniel C.Chief Commercial OfficerSSale−1.73K$15.37−$26.5K−3.4%49.3K after
Dec 14, 2023 (view filing)Dec 131 dayKelly Thomas PatrickChief Financial OfficerSSale−2.79K$15.37−$42.9K−3.9%68.5K after
Dec 14, 2023 (view filing)Dec 131 dayPitman JamaSee RemarksSSale−1.66K$15.37−$25.5K−3.1%52.2K after
Dec 14, 2023 (view filing)Dec 131 dayHoerter Steven L.President and CEOSSale−30.7K$15.37−$471.3K−29.6%72.8K after
Jan 18, 2024 (view filing)Jan 162 daysMartin Daniel C.Chief Commercial OfficerSSale−1.62K$14.47−$23.5K−3.3%47.7K after
Jan 18, 2024 (view filing)Jan 162 daysKelly Thomas PatrickChief Financial OfficerSSale−2.44K$14.47−$35.2K−3.6%66.1K after
Jan 18, 2024 (view filing)Jan 162 daysPitman JamaSVP, Chief Development OfficerSSale−1.62K$14.47−$23.5K−3.1%50.6K after
Jan 18, 2024 (view filing)Jan 162 daysSherman Matthew LEVP & Chief Medical OfficerSSale−2.44K$14.47−$35.2K−2.5%94.1K after